Jideytro offers new hope for ROS1-positive NSCLC after prior therapy

Written by The Life Science Feed Editorial Team · Published 24 July 2026 · Edited by William Lopes

ROS1-positive non-small cell lung cancer (NSCLC) represents a small but distinct subset of lung malignancies, often affecting younger patients and non-smokers. For these individuals, targeted therapies have reshaped prognosis, but options diminish significantly upon progression after initial treatment. The recent FDA approval of Jideytro offers a new therapeutic avenue for this challenging, previously treated population.

KEY TAKEAWAYS

- The Pivot: Jideytro provides a new targeted therapy option for patients with ROS1-positive NSCLC who have progressed on prior treatments.
- The Data: The objective response rate (ORR) was 52% (95% CI, 42-62) in previously treated patients.
- The Action: Clinicians should consider Jideytro for patients with ROS1-positive NSCLC whose disease has progressed following earlier systemic therapies.

Patients with advanced non-small cell lung cancer harbouring a ROS1 gene rearrangement face a difficult prognosis, particularly once their disease progresses on first-line targeted agents. These fusions drive oncogenesis, making them attractive targets for specific inhibitors. But resistance inevitably develops, leaving clinicians with limited effective strategies. The FDA's decision on Jideytro addresses this unmet need, expanding the therapeutic arsenal for a population with few remaining options.

The approval rests on data from a multi-cohort, open-label, multicentre Phase I/II study that enrolled patients with locally advanced or metastatic ROS1-positive NSCLC. The trial included both treatment-naïve and previously treated cohorts. For the purpose of this approval, the focus was on patients who had received prior systemic therapy, including chemotherapy or another ROS1 tyrosine kinase inhibitor (TKI). Investigators assessed objective response rate (ORR) and duration of response (DoR) as primary endpoints, with safety as a key secondary measure. The study included 130 patients in the previously treated cohort.

The clinical evidence for Jideytro

Jideytro demonstrated a clinically meaningful response rate in the previously treated cohort. The objective response rate (ORR) was 52% (95% CI, 42-62), meaning over half of these patients experienced a measurable reduction in tumour size. This included a complete response rate of 4% and a partial response rate of 48%. The median duration of response (DoR) was 14.5 months (95% CI, 10.1-20.1), indicating sustained benefit for those who responded to the therapy.

These numbers are particularly relevant for patients who have already progressed on other treatments. The drug's activity in the central nervous system (CNS) also warrants attention. In patients with measurable CNS metastases at baseline,

the intracranial ORR was 65% (95% CI, 48-79). This is a critical consideration, as brain metastases are common in ROS1-positive NSCLC and often represent a significant challenge in management. The ability of Jideytro to penetrate the blood-brain barrier and elicit responses in the CNS offers a distinct advantage.

Safety data from the trial showed Jideytro to be generally well-tolerated. The most common adverse reactions (occurring in ≥20% of patients) included nausea, fatigue, constipation, diarrhoea, and peripheral neuropathy. Grade 3 or 4 adverse events occurred in 35% of patients, with the most frequent being anaemia (5%), increased alanine aminotransferase (4%), and increased aspartate aminotransferase (4%). Discontinuation due to adverse reactions occurred in 12% of patients, with dose reductions required in 28%. These figures are consistent with the safety profiles of other TKIs in oncology, and clinicians should manage them proactively, as outlined in the prescribing information for Jideytro.

Where it fits in practice

The approval of Jideytro adds a valuable option to the treatment algorithm for ROS1-positive NSCLC. While first-generation ROS1 TKIs like crizotinib have been effective, resistance mechanisms often emerge, necessitating subsequent lines of therapy. Jideytro, as a next-generation TKI, offers a different mechanism of action or a broader spectrum of activity against common resistance mutations. This is not a drug for every lung cancer patient, but for the specific molecular subtype, it makes a difference.

Still, the open-label design of the pivotal study is the obvious caveat. While response rates and duration of response are compelling, the absence of a direct comparator arm means clinicians must interpret these results within the context of existing therapies and the natural history of the disease. The trial was also not powered to detect differences in specific resistance mutations, and that gap matters for future treatment sequencing. For a comprehensive understanding of oncology treatments, the Oxford Handbook of Oncology can be a useful reference.

The next trial needs to show how Jideytro performs head-to-head against other approved agents or in specific resistance mutation subgroups. This will clarify its optimal positioning in the evolving treatment landscape for ROS1-positive NSCLC.

CLINICAL IMPLICATIONS

The approval of Jideytro for previously treated ROS1-positive NSCLC is a clear win for patients and their oncologists. This is a rare cancer, and every new targeted agent extends life and improves quality of life for a population that historically had few options once first-line therapy failed. The sustained responses and CNS activity are particularly encouraging, addressing two major clinical challenges in this disease.

Clinicians should integrate Jideytro into their treatment planning for patients who have progressed on prior ROS1 inhibitors or chemotherapy. Molecular testing for ROS1 fusions remains paramount; without it, these patients miss out on highly effective targeted therapies. The drug's safety profile is manageable, aligning with expectations for this class of agents, but requires careful monitoring for common TKI-related adverse events.

The challenge now lies in understanding the optimal sequencing of ROS1 TKIs. With multiple agents available, the question of which drug to use after progression on a prior TKI, and against which specific resistance mutations, becomes increasingly complex. Real-world data and further head-to-head trials will be crucial to refine these treatment algorithms and ensure patients receive the most effective therapy at each stage of their disease.